Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by Spartrapon Jan 21, 2021 3:45pm
153 Views
Post# 32351039

RE:How did we lose $5 million in cash

RE:How did we lose $5 million in cash

Joke aside, the Coporate Presentation sates that $70M figure is from the cash position at August 31 ($26.8M) plus net proceeds from the offering ($46M - 6.25% = $43.13M).
Indeed, 26.8M + 43.13M = $69.93M

So if the CEO was talking about the current cash position, then we have to assume the cash position right before the offering was of about ~$22M.

So therefore, the company managed to burn around $4.8M of cash all the while it recorded its best quarter ever and didn't even have a trial running yet!
No wonder the board was trigger happy about that deal and so much for the legacy business not being important.

Because even in a bubble, even if investors would pour obscene amounts of money into the most crazy idea, there's one thing they would never ever want to fund on good terms: the losses from an unprofitable company.

SPCEO1 wrote: between the publishing of the corporate presentation this morning and the B. Riley presentation this afternoon? The corporate presentation says pro forma cash post the offering is $70 million while Paul mentioned $65 million on the B. Riley call. I hope they did not spend it on lunch today! 


 

<< Previous
Bullboard Posts
Next >>